BioTools Innovator

Enrich Therapeutics develops desktop cell isolation system for therapeutic discovery

By Samantha Black, PhD, ScienceBoard editor in chief

September 26, 2021 -- Enrich Therapeutics is developing a desktop static cell isolation technology that can separate clones to accelerate therapeutic discovery. We spoke with Dong Wang, who is co-founder, president, and chief operating officer of Enrich Therapeutics, as part of our coverage of the competition.

Enrich Therapeutics’ isolation technology does not involve forcing cells through a sorting process (which is a requirement for dynamic cell isolation). According to Wang, the company’s platform allows cells to settle in culture plates. This advantage allows cells to maintain their native state, and it is helpful for observation studies and when investigating cell-to-cell interactions. Importantly, the technology enables the capture of cells regardless of the cell culture method (adherent or suspension) used.

Video loading ...

The technology uses scalable, inexpensive but highly precise liquid crystal display to characterize irreversible chemical reactions that capture and protect individual cells with user-defined criteria. Wang explained that the platform’s isolation accuracy is very high; the entire process is visible on the instrument’s integrated microscope.

Enrich Therapeutics is one of 10 semifinalists that have the chance to win $200,000 in cash prizes in the BioTools Innovator accelerator contest, with the list of semifinalists released in late July. All semifinalists are assigned a mentor and will complete a curated curriculum designed to help them secure additional funding and elevate their companies. The field will be narrowed to four companies in early October. The four finalists will present at a live finale on October 14, 2021, where the audience will help decide the winner.

Stay tuned and follow along as we get a behind-the-scenes look at these companies as they race toward the finish!

Note: The BioTools Innovator accelerator contest is sponsored by Research Corporation Technologies and BroadOak Capital Partners, investors in's parent company, Science and Medicine Group.

Stellate carves out unique position in the gene editing field for large payloads
Stellate DNA is addressing the needs of the gene therapy and gene editing industries with its CRISPR technology that can deliver large payloads. The company...
Elemental Machines connects machines to managers with lab automation
The mission of Elemental Machines is to automate life science laboratories with technology that includes hardware, software, and artificial intelligence....
Kino Discovery is building an end-to-end solution for single-cell research
Kino Discovery is working on a tissue sample-to-cell solution to make personalized medicine a reality. The early-stage startup was founded by University...
Lino Biotech aims to improve cell therapy development, manufacturing
Switzerland-based Lino Biotech is leveraging its patented label-free biosensor technology to measure molecular interactions in living cells and biological...
MachineBio offers path toward single-step protein synthesis and purification
The next featured company in the BioTools Innovator accelerator contest is MachineBio. The company has developed a protein synthesis platform that can...

Copyright © 2021

HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter